key: cord-0310629-a28w3j2k
authors: Varotto-Boccazzi, I.; Manenti, A.; Dapporto, F.; Gourlay, L.; Bisaglia, B.; Gabrieli, P.; Forneris, F.; Faravelli, S.; Bollati, V.; Zuccotti, G. V.; Montomoli, E.; Epis, S.; Bandi, C.
title: Epidemic preparedness - Leishmania tarentolae as an easy-to-handle tool to produce antigens for viral diagnosis: application to COVID-19
date: 2021-07-07
journal: nan
DOI: 10.1101/2021.07.05.21260035
sha: 24f5ca650d75da2d7def282fabadf479407c9a60
doc_id: 310629
cord_uid: a28w3j2k

To control future epidemics, discovery platforms are urgently needed, for the rapid development of diagnostic assays. Molecular diagnostic tests for COVID-19 emerged shortly after the isolation of SARS-CoV-2, however, serological tests based on antiviral antibody detection, revealing previous exposure to the virus, required longer developmental phases, due to the need for correctly folded and glycosylated antigens. The delay between the identification of a new virus and the development of reliable serodiagnostic tools limits our readiness for the control of a future epidemic. In this context, we propose the protozoan Leishmania tarentolae as an easy-to-handle micro-factory for the rapid production of viral antigens, to be used at the forefront of emerging epidemics. As a study model, we engineered L. tarentolae to express the SARS-CoV-2 Receptor Binding Domain (RBD) and report the ability of the purified RBD antigen to detect SARS-CoV-2 infection, with a sensitivity and reproducibility comparable to that of a reference antigen produced in human cells. This is the first application of an antigen produced in L. tarentolae for the serodiagnosis of a Coronaviridae infection. Based on our results, we propose L. tarentolae as an effective system for viral antigen production, even in countries that lack high-tech cell factories.

The abrupt emergence of the COVID-19 pandemic has underlined the urgent need for new discovery 36 platforms for the rapid development of diagnostic and or monitoring tools, targeting infectious 37 diseases [1, 2] . Indeed, the effective containment of an infectious disease depends on the immediate 38 availability and application of diagnostic tools to detect infected individuals, as soon as possible after 39 the first confirmed cases have emerged [3] . In fact, within a few weeks after the isolation of the virus 40 responsible for COVID-19 (now called SARS-CoV-2), the viral genome had been sequenced [4-6] 41

and RT-qPCR diagnostic tools had been developed, for the detection of viral RNA [7] . In contrast, 42 the development of tools for the serological diagnosis of COVID-19, used to search for antibodies 43 against the virus in patient blood or serum, required more time, owing to the need to produce the 44 protein antigens to be implemented in the diagnostic tests [8, 9] . Protein antigens for serological 45 diagnosis are generally produced using recombinant DNA technology, after the engineering or 46 transfection of a cellular expression system for the production of the desired antigen [10-13]. The 47 most widely used systems for the production of recombinant protein antigens include prokaryotes 48 [17]). All these approaches have been employed for the production of different antigens from SARS-51

CoV-2 [18-22] and diagnostic kits, some of which are commercially available (e.g. see [23] ). 52

However, there is a general consensus that antigens produced in mammalian cells guarantee 53 optimal performances in the diagnosis of human viral diseases [12, 24] . Indeed, the most widely used 54 assays for the serological diagnosis of COVID-19 are based on antigens produced in human cells 55 (e.g. the HEK293 cells). The differences in the diagnostic performances of viral antigens produced 56 in mammalian cells, compared to those produced with other expression systems, mostly derive from 57 the glycosylation pattern of the proteins and their folding [24] . In this context, human cells transfected 58 with viral DNA are expected to produce protein antigens that are highly similar (or identical) to those 59 produced by a human virus during its natural infection cycle. Diversely, prokaryotic systems, such 60 as E. coli, are expected to produce non-glycosylated proteins, which would then potentially result in 61 altered patterns in antibody detection, when used in the serological diagnosis of viral diseases. The 62

Recombinant strains expressing Lt-RBD were cultured for four days in complete BHI supplemented 115 with Nourseothricin (100 μg/ml), Pen-Strep and hemin (1.25 µg/ml) at 26 °C in the dark and in 116 constant agitation under aerated conditions. The Leishmania cultures (2.5 L) were centrifuged for 10 117 min at 3.000 g, and the supernatant was filtered on a 47 mm diameter activated carbon filter (Merck) 118

(1 filter/0.5 L) to help remove the hemin from the growth media, prior to a second filtration step on a 119 0.22 µM nitrocellulose membrane (Merck). The supernatant was concentrated to approx. 100 mL 120 using the Vivaflow 200 system (Sartorius) and compatible PES Vivaflow 200 cassette (10,000 MW 121 cut-off), at 4°C, prior to dialysis, using a dialysis membrane with a MW cut-off of 14-16K (SpectaPor). 122

Dialysis was carried out at 4°C in 2.6 L Binding Buffer (20 mM sodium phosphate buffer pH 7.4, 123 containing 0.5 M NaCl and 0.01% (v/v) Tween-20). The dialysate was transferred into fresh buffer 124 (lacking Tween-20) after 4 hours, and then after a third exchange, overnight at 4 °C. Lt-RBD was 125 purified on a 5 mL HisTrap Excel column (Cytiva), pre-equilibrated with Binding Buffer. The 126

supernatant was loaded at a flow rate of 1 mL/min using AKTA basic FPLC (Cytiva) and washed 127

with Binding Buffer unit until the A280 nm reached baseline. Elution was carried out using a slow, 128 stepwise (1%, 3%, 5%, 10%, 15%, 20%, 30%, 50% 70% and 100%) imidazole gradient, generated 129 by mixing Binding Buffer with Elution Buffer (20 mM sodium phosphate buffer pH 7.4, 0.5 M NaCl 130 and 0.5 M imidazole), eluting at each step with 4 column volumes (CVs). Following SDS-PAGE 131 analysis, fractions containing the purified protein were pooled and concentrated to 500 μL, using an 132 Amicon Ultra Filter unit with a MW cut-off of 10,000 (Millipore) and further purified by size exclusion 133 chromatography on a Superdex 200 Increase 10/300 GL (Cytiva) column, pre-equilibrated in 1X PBS 134 (Merck) at a flowrate of 0.5 mL/min at RT. Peak fractions (1 mL/fraction) were pooled, and aliquoted 135 for conservation at -80 °C. Protein concentration was measured spectrophotometrically using a 136

Nanodrop, using the theoretically calculated A280 nm for 1 mg/mL Lt-RBD of 1.077) and with the 137 BCA Protein Assay Kit (Merck). 138

The expression of purified Lt-RBD was evaluated both by Coomassie staining and western blotting, 140 as described above. In particular, the proteins were transferred to nitrocellulose membranes (Bio-141

Rad Laboratories) which were incubated for 5 min at room temperature with EveryBlot Blocking 142 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint Buffer (Bio-Rad Laboratories) and then incubated with a 1:3000 dilution of anti-SARS/SARS-CoV-2 143

Coronavirus Spike Protein (subunit 1) Antibody (Thermo Fisher) in the blocking buffer for 1 h. After 144 three washes with PBS + 0.1% (v/v) Tween-20 (PBS-T), the membrane was incubated with a 145 horseradish peroxidase (HRP)-conjugated IgG anti-rabbit 1:30,000 (Thermo Fisher) in the blocking 146 buffer for 1h. Finally, after three washes with PBS-T, the membrane was incubated for 5 min with 147 the Clarity Western ECL Substrate (Bio-Rad Laboratories) and detected by ChemiDoc Touch 148

Imaging System (Bio-Rad Laboratories). 149

For comparative analyses of glycosylation and molecular weight determination (see below), we 151 recombinantly produced RBD in human cells (hu-RBD), to simulate the viral protein produced during 152 a natural infection in humans. Briefly, hu-RBD was produced in the HEK293-F line (Invitrogen), 153 cultivated in suspension using Freestyle medium (Invitrogen) according to [34] and then purified, 154

following the procedure described in [35] . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint (NanoTemper Technologies GmbH). Data were analyzed and plotted using the GraphPad Prism 7 170 (Graphpad Software). 171

IgG/IgM human serum sample from a convalescent COVID-19 subject was purchased from BIOIVT 173 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. 

Precision of the assay was assessed by testing positive control as neat and pre-diluted 1:2, 1:4, 1:8, 223

1:16, 1:32, 1:64 and 1:128 in dilution buffer; thus, considering the sample in first well is always diluted 224 1:100, the effective samples starting dilution in the first well will be 1:100 1:200, 1:400, 1:800, 1:1600, 225 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint 1:3200, 1:6400, 1:12800. The above-mentioned sample dilutions will be tested eight times in two 226 different plates from one operator on day 1 (four repetitions per plate); the RP value will be calculated 227 between two determination results from the two different plates. The same testing activity will be 228 performed by another operator on day 2 to obtain a total of eight reportable values for each dilution 229 (four RP values from operator 1 and four RP values from operator 2). 230 

The accuracy of the test was evaluated using the reportable values obtained for the evaluation of 237 the Precision. According to ICH guideline Q2 [36] , the accuracy can be tested using either a 238 conventional true value or an accepted reference value. The true value was calculated from the 239 linearity result as GMT between the 8 HP-HS RPs: the GMT result of reportable values from the neat 240 sample were divided for the respective dilution factor to be investigated and compared with the real 241 obtained value during testing (as GMT between the obtained RPs). Relative accuracy was evaluated 242 by calculating the percentage of recovery on the GMT of the RP and the expected (true) titre obtained 243 using this formula: 100*(GMT observed / GMT expected) 244

Plates are incubated for 30 min (standard condition) with detection antibody to detect IgG 246 specifically; in order to assess the influence of this incubation time, plates were incubated with the 247 dilution antibody for 30 min at 37°C and two other different times: 20 min and 40 min. 248

The positive and negative controls were tested with a starting dilution of 1:100 in four repetitions, in 249 two plates in two different days for each condition to obtain four reportable values. 250

Specific anti-SARS-CoV-2 IgG antibodies in human sera were detected by means of an in-house 252 RBD assay using Lt-RBD produced in L. tarentolae cells and com-RBD, produced from HEK 293 253 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. for SARS-CoV-2, five low positive for SARS-CoV-2 and five pre-pandemic negative for SARS-CoV-257

2) were tested starting from 1:100 to 1:25600 dilutions. The comparative assays were performed as 258 described above. Briefly, ELISA plates were coated with Lt-RBD-SD1 (2 μg/ml) or commercial RBD 259 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint estimated MW; this band was visible for most of the tested clones (Figure 1(a) ). The supernatant 281 from the non-engineered L. tarentolae-P10 parasite was used as a negative control. The most 282 productive clone was selected for large scale (2.5 L) expression and purification, via affinity 283 chromatography and size exclusion chromatography (materials and methods). Large scale 284 expression of Lt-RBD resulted in a yield of approx. 2,3 mg/L culture. The protein was identified by 285

Western blotting using a specific anti-RBD antibody (Figure 1(b) ) and judged to be pure by 286

Coomassie blue staining (Figure 1(c) ). 287

SEC-MALS analysis showed that the purified protein is monodisperse with a total molecular weight 289 of 36.5 kDa, which is 5 kilodaltons greater than the molecular weight predicted on the basis of amino 290 acid composition, due to the glycan moieties ( Figure 2 

The difference between the molecular masses of the two proteins is mainly due to the inclusion of 301 the SD1 subdomain in Lt-RBD. Furthermore, their unfolding temperatures, determined by DSF 302 analysis, are highly similar (Lt-RBD-SD1: 53.2 °C; hu-RBD: 53.4 °C), indicating that Lt-RBD is as 303 stable as the hu-RBD protein (Figure 3) . 304 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint

The RBD-ELISA qualification assay was carried out, as described by [39] . Purified recombinant Lt-306 RBD was tested for its ability to detect specific human antibodies. The protein was evaluated using 307 four coating concentrations (1, 2, 3 and 4 μg/mL). The optimal concentration chosen for antigen 308 coating was 2 μg/mL and the optimal dilution for the secondary HRP conjugated anti-human IgG 309 was 1:100,000. 310

The specificity was determined as the ability of the assay to differentiate between similar analytes 312 and in particular to differentiate the target analyte from non-target analytes [40] . In order to determine 313 the specificity of the method for anti-SARS-CoV-2 IgG antibodies, positive samples for homologous 314 and heterologous viruses/pathogens were tested. The ELISA specificity was evaluated testing the 315 samples reported in Table 2 319 320

The negative sample, as the heterologous sample, showed negative titres in all performed is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. Table S1 indicate that the assay is specific. 327

The precision of an analytical procedure is generally defined as the standard deviation or relative 329 standard deviation (coefficient of variation) of a series of measurements [36, 41] . The standard 330 deviation may be evaluated at three levels: repeatability, intermediate precision and reproducibility. 331

Repeatability (also called intra-assay precision) shows the precision of the assay when the test is 333 carried out in a laboratory over a relatively short time period using the same operator and equipment. The %GSD, between four reportable values from each operator (in one experiment on the same 336 day) from the precision experiment, was calculated and reported for each dilution, for each operator. 337

The negative sample provided negative titre results. The positive sample showed GSD% <50% for 338 all dilutions (Table S2 ). These results indicate that the assay is repeatable for intra-assay precision 339 parameters. 340

The purpose of intermediate precision is to determine the capacity of the assay to provide dilutions, which indicates that the assay meets the criteria for intermediate precision (Table S3) . 348

The term "linearity" refers to the linearity of the relationship between the concentration and the assay The aim of linearity is to provide a model, linear or not, that is suitable to illustrate the relationship 353 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. showing an absolute value between 0.7 and 1.3. In the case of a significant non zero intercept, it is 356 necessary to demonstrate that it does not have consequences on the accuracy of the assay [40] . 357

The correlation between sample dilutions and corresponding reportable values, in the full dilutions 358 range applied (1:100 -1:12800), was high, in that the coefficient of determination R2 was close to 1 359 (0.995), while the absolute value of the slope was 1.090 (Table S4 ; Figure S1) . 360

The assay quantitation range is the range within which the assay has demonstrated to have a 362 suitable level of precision and accuracy. In detail, this range is defined by the lower and the upper 363 sample dilutions able to provide linear and accurate results in agreement with the acceptability 364 requirements. Although the last dilution points are almost all below the limit of detection, considering 365 that the inter-assay and intra-assay precision are confirming the assay repeatability, the results of 366 this validation process indicate that the assay is linear and precise along the whole range of dilutions 367 applied in this validation resulting in a titer range between 71.0 and 14061.8, (calculated as the GMT 368 between the neat HP-HS results in precision experiments) corresponding to the closest dilutional 369 point of 100 and 26,500, respectively (Table S5) . Although the last dilution point (1/128) is below the 370 detection limit, the recovery value for each sample dilution was excellent. 371

The robustness gives an indication of the assay reliability when events could occur during testing in 373 a single laboratory. Plates are incubated for 20, 30 and 40 min in order to assess the influence of 374 this incubation time with HRP. For the three different conditions of incubation time for antibody 375 detection, the %GSD of the results for the positive control was <50% and the negative control 376 showed negative results, hence the results indicate that the assay is robust (Table S6 ). The 377 qualification process of this specific IgG ELISA test for SARS-CoV-2, set-up with the use of the Lt-378 RBD protein produced in L. tarentolae, fulfilled all the acceptability criteria. In particular, the assay 379 demonstrated to be: specific, reproducible, precise, linear, accurate, and robust. Thus, the procedure 380 is defined as reliable and valid for the serological detection of SARS-CoV-2 IgG-specific antibodies. 381 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint

The ability of Lt-RBD-SD1 to detect antibodies in comparison with the commercial RBD produced in 383 HEK cells (com-RBD) was evaluated testing fifteen human sera, among which five high positive and 384 five low positive for SARS-CoV-2. As negative controls, five pre-pandemic (2015) sera were included 385 in the assay. The IgG antibody titers were calculated, and the results obtained with the two proteins 386

were compared. As shown in Figure 4 the results, expressed as titres were highly congruent and the 387 curves showing the trend of the results among samples exactly the same. 388

In addition, a cohort of eighty human sera, from asymptomatic COVID-19 subjects and from subjects 389 that had no history of SARS-CoV-2 infection, tested negative by PCR in previous assays, were tested 390 comparing Lt-RBD and com-RBD. Each serum was evaluated at 1:100 dilution by means of in-house 391 ELISA assay. A serum sample was considered positive when its OD450 value was above the 392 established cut-off (see materials and methods). The results of the qualitative analysis show an 393 agreement in approximately 99% of the samples tested with the two different proteins (Table 3) . 394 Negative Negative . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. The success in the serodiagnostic use of antigens produced in L. tarentolae to detect Leishmania 415 spp. or Trypanosoma spp. infections does not guarantee the efficacy of this protein microfactory as 416 a source of antigens for infectious diseases caused by other pathogens. Using SARS-CoV-2 as a 417 study system, our present work provides the first, sound evidence on the potential utility of L. 418 tarentolae as a micro-factory to produce antigens for serodiagnosis of Coronaviridae infections. To 419 summarize our results: i) the model antigen that we selected for this study, i.e. the RBD protein from 420 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. obtained with com-RBD; iv) finally, qualitative analysis with Lt-RBD on 80 sera from a previous study 428 led to an almost perfect match with the results obtained with com-RBD (with just one mismatch). 429

The gold standard for serological diagnosis of human and mammalian viruses is the use of antigens 430 produced in mammalian cells [12, 18, 19, 24] . However, the use of mammalian cells for the production 431 of viral antigens presents potential limitations, in particular for rapid application and fast production 432 in developing countries: highly specialized cell factories are indeed needed for efficient protein 433 production in mammalian cells, and production costs are relatively high, compared to microbial-434 based systems. Our study underlines L. tarentolae as a system that is easy to manipulate and 435 culture, providing a sound alternative for the rapid production of serodiagnostic proteins, even at the 436 forefront of novel epidemics, e.g. in the presence of "spillover" events in tropical countries [42] . 437

Accordingly, we emphasize that L. tarentolae can produce high protein yields that can easily be 438 increased to industrial scale, by growing the parasites in bioreactors and harvesting proteins using CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 7, 2021. ; https://doi.org/10.1101/2021.07.05.21260035 doi: medRxiv preprint

Highlights from a year in a pandemic

Insights into the recent 2019 novel coronavirus 471 (SARS-CoV-2) in light of past human coronavirus outbreaks

COVID-19 Strategic preparedness and response plan. COVID-473 19 strategic preparedness and response plan (SPRP 2021)

Genomic characterisation and epidemiology of 2019 novel coronavirus: 477 implications for virus origins and receptor binding

A new coronavirus associated with human respiratory disease in China

An Update on molecular diagnostics for COVID-19

Antibody responses to SARS-CoV-2 in patients with

Diagnostic performance of seven rapid IgG/IgM 485 antibody tests and the euroimmun IgA/IgG ELISA in COVID-19 patients

Select what you need: a comparative evaluation of the advantages and 490 limitations of frequently used expression systems for foreign genes

Recent developments in bioprocessing of recombinant proteins: 493 expression hosts and process development

Recombinant proteins for industrial versus pharmaceutical purposes: a 495 review of process and pricing

Recombinant protein expression in Escherichia coli: advances and 497 challenges

Recombinant protein production in yeasts

Recombinant Gene Expression. methods in molecular biology

Protein expression in the baculovirus system

Gene expression in mammalian cells and its applications

Cryo-EM structure of the 2019-nCoV spike in the prefusion 506 conformation

function, and antigenicity of the SARS-CoV

Characterization of the receptor-binding domain (RBD

Efficient production of recombinant SARS-CoV-2 spike protein 513 using the baculovirus-silkworm system

Expression, purification and immunological 515 characterization of recombinant nucleocapsid protein fragment from SARS-CoV-2

SARS-CoV-2 infection 518 among asymptomatic homebound subjects in

Recombinant pharmaceuticals from microbial 520 cells: a 2015 update

Recombinant protein production in the eukaryotic protozoan parasite Leishmania 522 tarentolae: a review

Non-conventional expression systems for the production 524 of vaccine proteins and immunotherapeutic molecules

Leishmania tarentolae: taxonomic classification and 526 its application as a promising biotechnological expression host

Expression of a truncated hepatitis E virus capsid 529 protein in the protozoan organism Leishmania tarentolae and its application in a serological assay

Expression of Trypanosoma brucei gambiense antigens 532

Potential for use in rapid serodiagnostic tests (RDTs)

Production of a kinesin-related recombinant protein 535 40. World Organisation for Animal Health, O.I.E. 2013. Principles and methods of validation of 559 diagnostic assays for infectious diseases. Manual of Diagnostic Tests and Vaccines for Terrestrial 560

Version adopted by the World Assembly of Delegates of the OIE

United States Pharmacopeia

In section 1225

Host and viral traits predict zoonotic spillover 564 from mammals

The authors thank Prof. M. Bolognesi from University of Milan (Dept. Biosciences) for his